Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAERS Funding Flat While Drug Safety Increases In FDA Spending Bill

This article was originally published in The Tan Sheet

Executive Summary

The Agriculture Appropriations conference report approved by the House and Senate includes $5.36 mil. for the CFSAN Adverse Events Reporting System, "of which approximately $1.5 mil. is for dietary supplements.

You may also be interested in...



Spending Bill Addresses Conflict Waivers, Sunscreen Monograph

FDA will be required to publicly disclose the rationale behind any advisory committee conflict of interest waivers under an amendment to the Senate version of the agency's spending bill

Dietary Supplement Mandatory AER System Cost Estimate Sought By Senators

The Senate Appropriations Committee requests information on the cost of a mandatory adverse event reporting system for dietary supplements in its report accompanying FY 2006 budget legislation for FDA

Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date

FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel